London
· Delayed Price · Currency is GBP · Price in USD TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of GBP 5.19 billion. The enterprise value is 5.15 billion.
| Market Cap | 5.19B |
| Enterprise Value | 5.15B |
Important Dates
The next estimated earnings date is Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.96% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 148.20M |
Valuation Ratios
The trailing PE ratio is 277.77.
| PE Ratio | 277.77 |
| Forward PE | n/a |
| PS Ratio | 19.74 |
| PB Ratio | 29.21 |
| P/TBV Ratio | 29.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 154.43, with an EV/FCF ratio of -158.81.
| EV / Earnings | 275.49 |
| EV / Sales | 20.79 |
| EV / EBITDA | 154.43 |
| EV / EBIT | 163.15 |
| EV / FCF | -158.81 |
Financial Position
The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.
| Current Ratio | 6.25 |
| Quick Ratio | 4.85 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 5.74 |
| Debt / FCF | -6.27 |
| Interest Coverage | 1.75 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 7.00%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 5.78% |
| Return on Invested Capital (ROIC) | 7.00% |
| Return on Capital Employed (ROCE) | 8.61% |
| Revenue Per Employee | 777,510 |
| Profits Per Employee | 55,259 |
| Employee Count | 338 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +138.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +138.40% |
| 50-Day Moving Average | 32.07 |
| 200-Day Moving Average | 23.65 |
| Relative Strength Index (RSI) | 66.40 |
| Average Volume (20 Days) | 3,606 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.50 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of GBP 262.80 million and earned 18.68 million in profits. Earnings per share was 0.12.
| Revenue | 262.80M |
| Gross Profit | 232.06M |
| Operating Income | 33.49M |
| Pretax Income | 20.44M |
| Net Income | 18.68M |
| EBITDA | 33.55M |
| EBIT | 33.49M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 248.42 million in cash and 203.19 million in debt, giving a net cash position of 45.23 million.
| Cash & Cash Equivalents | 248.42M |
| Total Debt | 203.19M |
| Net Cash | 45.23M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 177.62M |
| Book Value Per Share | 1.23 |
| Working Capital | 379.96M |
Cash Flow
In the last 12 months, operating cash flow was -32.36 million and capital expenditures -35,945, giving a free cash flow of -32.40 million.
| Operating Cash Flow | -32.36M |
| Capital Expenditures | -35,945 |
| Free Cash Flow | -32.40M |
| FCF Per Share | n/a |
Margins
Gross margin is 88.30%, with operating and profit margins of 12.74% and 7.11%.
| Gross Margin | 88.30% |
| Operating Margin | 12.74% |
| Pretax Margin | 7.78% |
| Profit Margin | 7.11% |
| EBITDA Margin | 12.76% |
| EBIT Margin | 12.74% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.96% |
| Shareholder Yield | -7.96% |
| Earnings Yield | 0.36% |
| FCF Yield | -0.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TG Therapeutics has an Altman Z-Score of 3.11.
| Altman Z-Score | 3.11 |
| Piotroski F-Score | n/a |